You may qualify to participate in a national research study to evaluate the safety and effectiveness of the shingles vaccine (Zostavax®). Are you at least 50 years old? Are you taking Remicade, Enbrel, Humira, Cimzia or Simponi? If yes, and if you have never received the shingles vaccine, you may qualify. The duration of the study is 6 months. Participants will be compensated. Zostavax ® is an approved vaccine for people ages 50 and older and has been shown to be very effective to prevent zoster (shingles) and related complications. However it has NOT been studied in patients who are taking Remicade, Enbrel, Humira, Cimzia or Simponi. The Varicella zostER VaccinE Study (VERVE) has been approved by the Food and Drug Administration (FDA). UAB is coordinating the VERVE study. For more information, please call (205) 934-2993 or email
If you are due to receive your MMR vaccination and are ages 18 or older, are healthy, without autoimmune disorders (non-immunocompromised), have never had an allergic reaction to any vaccine, and you are willing to have blood drawn three times during the study then you may qualify for a clinical trial seeking to identify biomarkers that may help researchers improve the effectiveness of the MMR vaccine. Eligible participants will receive the FDA-approved MMR immunization and then have blood drawn 3 times, one week apart. Compensation is provided for each completed study visit. For more information or to see if you qualify, call (205) 996-4099.
The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant. This study is open to healthy adults ages 19-64 who have not already received the 2017-2018 flu vaccine. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into. Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period. For more information or to see if you qualify for this study, please contact us at 205-934-6777 or 205-996-4099

Safety Resources